Changes in Circulating Immature and Mature Dendritic Cells During IL-2 Cancer Immunotherapy and Their Relation with Lymphocyte Increase and Clinical Response

References

• Palmer, P. A., Atzpodien, J., Philip, T., Negrier, S., Kirchner, H., Von der Maase, H., Geertsen, P., Evers, P., Loriaux, E., Oskam, R., Roest, G., Vinke, J. and Franks, C. R. (1993). A comparison of 2 modes of administration of rIL-2: continuous intravenous infusion alone versus subcutaneous administration plus IFN-a in patients with advanced renal cell carcinoma. Cancer Bioth, 8(2), 123–35.
   PubMedGoogle Scholar
• Gohring, B., Riemann, D., Rebmann, U., Heynemann, H., Schabel, J. and Langner, J. (1996). Prognostic value of immunomonitoring of patients with renal cell carcinoma under therapy with IL-2/IFN-a in combination with 5FU. Urol. Res, 24, 297–303.
   PubMed Web of Science ®Google Scholar
• Jeal, W. and Goa, K. L. (1997). Aldesleukin (recombinant Interleukin-2). A review of its pharmacological properties, clinical efficacy and tolerability in patients with renal cell carcinoma. BioDrugs, 7(4), 285–317.
   PubMed Web of Science ®Google Scholar
• Fumagalli, L., Lissoni, P., Di Felice, G., Meregalli, S., Valsuani, G., Mengo, S. and Rovelli, F. (1999). Pretreatment serum markers and lymphocyte response to interleukin-2 therapy. Br. J. Cancer, 80, 407–411.
   PubMed Web of Science ®Google Scholar
• Marincola, F. M. (1997). The multiple ways to tumor tolerance. J. Immunother, 20, 178–179.
   PubMed Web of Science ®Google Scholar
• Porgador, A., Snyder, D. and Gilboa, E. (1996). Induction of antitumor immunity using bone marrow-generated dendritic cells. J. Immunol, 156, 2918–2926.
   PubMed Web of Science ®Google Scholar
• Di Nicola, M., Anichini, A., Mortarini, R., Bregni, M., Parmiani, G. and Gianni, A. M. (1998). Human dendritic cells: natural adjuvants in antitumor immunotherapy. Cytok. Cell. Mole. Ther, 4, 265–273.
   PubMedGoogle Scholar
• Peters, J., Gieseler, R., Thiele, B. and Steinbach, F. (1996). Dendritic cells: from ontogenetic orphans to myelomonocytic descendants. Immunol. Today, 17, 277–278.
   Google Scholar
• Grimm, E., Mazumder, A., Zhang, H. Z. and Rosenberg, S. A. (1982). Lymphockine-activated killer cell phenomenon. J. Exp. Med, 155, 1823–1841.
   PubMed Web of Science ®Google Scholar
• Wigginton, J. M., Koschlies, K. L., Back, T. C, Franco, J. L., Brunda, M. J. and Wiltrout, R. H. (1996). Administration of interleukin-12 with pulse interleukin-2 and the rapid and complete eradication of murine renal carcinoma. J. Natl. Cancer Inst, 88, 38–43.
   PubMed Web of Science ®Google Scholar
• Kishi, A., Ohmori, M., Tomita, S., Niman, M., Uno, K., Tanigawa, M., Setoguchi, J., Nitta, H., Ikeda, T., Kishida, T. and Fujita, S. (1999). Phenotypic and functional analyses of natural killer cells: impaired NK activity partly due to the CD56+ cell dysfunction in cancer patients. Int. J. Immunother, XV, 1–12.
   Google Scholar
• Lotze, M. T., Hellerstedt, B., Stolinski, L., Tueting, T., Wilson, C., Kinzler, D., Vu, H., Rubin, J. T., Strokus, W., Tahara, H., Elder, E. and Whiteside, T. (1997). The role of interleukin-2, interleukin-12 and dendritic cells in cancer therapy. Cancer J. Sci. Am, 3, S109–S114.
   PubMed Web of Science ®Google Scholar
• Lissoni, P., Barni, S., Ardizzoia, A., Crispino, S., Paolorossi, F., Archili, C., Vaghi, M. and Tancini, G. (1992). Second-line therapy with low-dose subcutaneous interleukin-2 alone in advanced renal cancer resistant to interferon-alpha. Eur. J. cancer, 28, 92–96.
   PubMed Web of Science ®Google Scholar
• O'Doherty, U., Peng, M., Gezelter, S., Swiggard, W. J., Betjes, M., Bhardway, N. and Steinman, R. M. (1994). Human blood contains two subsets of dendritic cells, one immunologically mature and the other immature. Immunology, 82, 487–493.
   PubMed Web of Science ®Google Scholar
• Savary, C. A., Grazziutti, M. L., Melichar, B., Przepiorka, D., Freedman, R. S., Cowart, R. E., Cohen, D. M., Anaissie, E. J., Woodside, D. G., McIntyre, B. W., Pierson, D. L., Pellis, N. R. and Rex, J. H. (1998). Multidimensional flow-cytometric analysis of dendritic cells in the peripheral blood of normal donors and cancer patients. Cancer Immunol Immunother, 45, 234–240.
   PubMed Web of Science ®Google Scholar
• Lissoni, P., Fumagalli, L., Rovelli, F., Brivio, F., Di Felice, G. and Majorca, F. (1998). In vivo stimulation of IL-12 secretion by subcutaneous low-doses IL-2 in metastatic cancer patients. Br. J. Cancer, 77, 1957–1960.
   PubMed Web of Science ®Google Scholar
• Capelli, E., Nano, R. and Barni, S. (1997). Dendritic cell differentiation in a peripheral blood mononucleated cell culture treated with interleukin-2. Hematologica, 82, 634.
   PubMed Web of Science ®Google Scholar
• Ferrara, N., Houck, K. A., Jakeman, L. B., Winer, L. and Leung, D. W. (1996). The vascular endothelial growth factor family of polypeptides. J. Cell. Biochem, 47, 211–218.
   Web of Science ®Google Scholar
• Gabrilovich, D. I., Chen, H. L., Girgis, K. R., Cunningham, H. T., Meny, G. M., Nadaf, S., Kavanaugh, D. and Carbone, D. P. (1996). Production of vascular endothelial growth factor by human tumor inhibits the functional maturation of dendritic cells. Nat. Med, 2, 1096–1103.
   PubMed Web of Science ®Google Scholar
• Lissoni, P., Fumagalli, L., Giani, L., Rovelli, F., Confalonieri, G. and Pescia, S. (1998). Vascular endothelial growth factor (VEGF) serum levels during cancer immunotherapy with IL-2: preliminary considerations. Int. J. Biol. Markers, 13, 98–101.
   PubMed Web of Science ®Google Scholar
• Blay, J. Y., Pallardy, M., Ravaud, A., Caux, C., Négrier, S., Douillard, J. Y., Chevreaux, C., Fleury, J., Ray, I., Escudier, B. and Lasset, C. (1999). Serum VEGF is an independent prognostic factor in patients with metastatic renal carcinoma treated with IL-2 and/or IFN-alpha: analysis of the Crecy trial. Proc. Am. Soc. Clin. Oncol, 18, 1669 (abstr.).
   Google Scholar